Aller au contenu principal
Accès ouvert déclaré 2026 article

Clinical, genetic, and familial features of POT1 tumor predisposition syndrome

2Citations signalées, ce qui n’est pas une note de qualité
2Institutions déclarées
1Pays d’affiliation déclarés

Rattachement africain : us. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

BACKGROUND: Protection of telomere 1 (POT1) tumor predisposition syndrome (POT1-TPD) is a hereditary leukemia syndrome that is identified in ∼5% of patients with chronic lymphocytic leukemia (CLL) and is characterized by a predisposition to other cancers, including gliomas, melanomas, and angiosarcomas. This study reports clinical and genetic characteristics of a large cohort of individuals with POT1-TPD. MATERIALS AND METHODS: Individuals with pathogenic/likely pathogenic germline POT1 variants referred to the Hereditary Hematologic Malignancy Clinic at The University of Texas MD Anderson Cancer Center were included. Individuals with variants of uncertain significance were included if found to have telomeres >90th percentile of age-predicted length. RESULTS: Twenty-four individuals in 17 families were identified. At referral, 11 (46%) had CLL and one (4%) had monoclonal B-cell lymphocytosis (MBL). The remaining 12 individuals had no history of CLL/MBL; however, four (33%) were discovered to have MBL at the time of referral. Among the 17 families, melanoma (47%), CLL (35%), and glioblastoma (18%) were prevalent. Five families had telomere length testing (31%), with lymphocyte telomere lengths >99th percentile in 60% and >90th percentile in 100%. Patients with CLL (n = 11) had a median age at diagnosis of 55 years (range, 29-68). A total of 82% had diploid karyotype, 64% had del13q by fluorescence in situ hybridization, and 60% had mutated immunoglobulin heavy chain variable region. Five patients (45%) received treatment for CLL, with a median time-to-treatment of 4.5 years (95% CI, 4.3-4.6). CONCLUSION: This analysis provides insights into the clinical features and familial patterns of malignancy of individuals with POT1-TPD. Identification through genetic counseling and augmented cancer screening is paramount.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé, mais le titre doit être comparé manuellement.

Titre Crossref
Clinical, genetic, and familial features of <i>POT1</i> tumor predisposition syndrome
Date Crossref
13/02/2026
Éditeur
Wiley
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Les institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Acute Myeloid Leukemia ResearchChronic Lymphocytic Leukemia ResearchTelomeres, Telomerase, and Senescence

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.